After the recent rights issue, Ascelia has a cash position of SEK 95.7m, and the company has a runway to end 2025. The Full Study Report for Orviglance is completed, and the next stage is to engage in pre-submission meetings with the FDA on the way to a formal submission by mid-2025. Orviglance continues to feature at conferences, which is important as Ascelia is pursuing a partner strategy for the future launch of Orviglance.